معرفی
Professor Alessio Ciulli is a leading academic in Chemical and Structural Biology at the University of Dundee’s School of Life Sciences. He holds a Personal Chair and directs the Centre for Targeted Protein Degradation (CeTPD), a research hub pioneering next-generation therapeutics through targeted protein degradation (TPD) and proximity-based pharmacology. Ciulli’s work focuses on designing small molecules that induce protein degradation, particularly via PROTACs, targeting oncogenic proteins and undruggable disease pathways. He co-founded Amphista Therapeutics, a biotech spin-off advancing protein degradation platforms.
Education & Career:
- BSc (Magna Cum Laude) in Chemistry, University of Florence (2002)
- PhD in Biophysical Chemistry, University of Cambridge (2006), supervised by Chris Abell and Glyn Williams
- Postdoctoral fellowships at University of Cambridge and Yale University (via HFSP Fellowship)
- Joined Dundee in 2013 as Reader (Associate Professor), promoted to full Professor (2016)
Research Interests:
- PROTAC design and mechanism optimization
- Targeting protein-protein interactions (PPIs)
- Epigenetic reader domains (e.g., BET, Bromodomain)
- Fragment-based drug discovery
- Chemical probes for biological systems
Key Achievements:
- 2025 Royal Society Fellowship (FRS)
- 2023 Royal Society of Edinburgh Fellowship (FRSE)
- ERC Starting Grant (2012), BBSRC David Phillips Fellowship (2009)
- Over 100 peer-reviewed papers, patents, and drug discovery collaborations (e.g., Boehringer Ingelheim)
Grants & Collaborations:
- EU-funded consortia on tuberculosis drug discovery (2006–2009)
- Industry partnerships for PROTAC development
- Funding from Royal Society, Wellcome Trust, and others
Labs & Teams:
- CeTPD integrates 20+ researchers, postdocs, and students
- Develops chemical tools and preclinical models for TPD
- Hosts the Journal Club, a student-led initiative analyzing TPD literature
۰مقاله منتشرشده
